Home  |  Contact

Cellosaurus MSTO-211H (CVCL_1430)

Cell line name MSTO-211H
Synonyms MSTO-211 H; MSTO211H; MSTO-211; 211H
Accession CVCL_1430
Resource Identification Initiative To cite this cell line use: MSTO-211H (RRID:CVCL_1430)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
Doubling time: ~30-40 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Pleural effusion.
Sequence variations LATS2 c.2355_2396del42 (PubMed=21245096).
Disease Pleural biphasic mesothelioma (NCIt: C45665)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 62Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ

Markers:
AmelogeninX,Y
CSF1PO11,12
D13S31711,14
D16S53913
D18S5116,18
D21S1128,31
D3S135815
D5S81812
D7S8208,12
D8S117913
FGA21
Penta D11,12
Penta E7,13
TH018,9.3
TPOX11
vWA16,18
Publications

PubMed=2840315; DOI=10.1111/j.1432-0436.1988.tb00806.x
Bepler G., Koehler A., Kiefer P., Havemann K., Beisenherz K., Jaques G., Gropp C., Haeder M.
Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.
Differentiation 37:158-171(1988)

PubMed=15920167; DOI=10.1016/S0002-9440(10)62492-3
Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G., Sugarbaker D.J., Bueno R.
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
Am. J. Pathol. 166:1827-1840(2005)

PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x
Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Cancer Sci. 97:387-394(2006)

PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x
Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K., Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M., Sekido Y.
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
Cancer Sci. 98:438-446(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)

PubMed=21642991; DOI=10.1038/ng.855
Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., Zhou Q., Shen R., Olshen A.B., Rusch V., Ladanyi M.
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-672(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24926545; DOI=10.1097/JTO.0000000000000202
Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y., Rice D.C., Tsao A., Wistuba I.I.
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
J. Thorac. Oncol. 9:998-1007(2014)

PubMed=26011428; DOI=10.1111/cas.12698
Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y., Yokoi K., Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Cancer Sci. 106:990-999(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28553954; DOI=10.1038/onc.2017.147
Kato T., Sato T., Yokoi K., Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Oncogene 36:5522-5531(2017)

Cross-references
Cell line collections ATCC; CRL-2081
CLS; 300450/p759_MSTO-211H
DSMZ; ACC-390
ICLC; HL01018
Cell line databases/resources CLDB; cl7174
CCLE; MSTO211H_PLEURA
Cosmic-CLP; 908152
GDSC; 908152
LINCS_LDP; LCL-1776
Ontologies BTO; BTO:0002425
CLO; CLO_0007880
EFO; EFO_0002839
Biological sample resources BioSample; SAMN03471440
BioSamples; SAMEA100779
Chemistry resources ChEMBL-Cells; CHEMBL3308116
ChEMBL-Targets; CHEMBL1075509
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM49614
GEO; GSM726279
GEO; GSM827586
GEO; GSM850286
GEO; GSM887342
GEO; GSM888418
GEO; GSM1670136
Other Wikidata; Q54906900
Polymorphism and mutation databases Cosmic; 688057
Cosmic; 877275
Cosmic; 908152
Cosmic; 1067228
Cosmic; 1175876
Cosmic; 1481542
Cosmic; 1522772
Cosmic; 1541211
Cosmic; 1749563
Cosmic; 1963324
Cosmic; 1995515